J84.842 Pulmonary interstitial glycogenosis

Name of the Condition

• Pulmonary interstitial glycogenosis

Summary

Pulmonary interstitial glycogenosis is a rare pediatric interstitial lung disease characterized by the accumulation of glycogen-rich cells in the lung interstitium. This condition primarily affects infants and young children, leading to impaired gas exchange and respiratory symptoms. The disease involves abnormal cellular changes in the tissue surrounding the air sacs (alveoli), which can disrupt normal lung function.

Causes

The exact cause of pulmonary interstitial glycogenosis is not fully understood. It is thought to result from developmental abnormalities in lung tissue, possibly related to immature or dysregulated cell growth during early life. In some cases, it may occur alongside other congenital or genetic conditions, though no specific genetic mutations have been consistently identified.

Risk Factors

• Prematurity or low birth weight.
• Neonatal respiratory distress or oxygen therapy.
• Underlying congenital anomalies affecting lung development.
• Family history of interstitial lung diseases (rare).

Symptoms

• Rapid or labored breathing (tachypnea or dyspnea).
• Intermittent or persistent cough.
• Poor weight gain or failure to thrive.
• Cyanosis (bluish skin due to low oxygen).
• Recurrent respiratory infections.

Diagnosis

Diagnosis requires a combination of clinical evaluation, imaging (e.g., chest X-ray or CT scan), and lung biopsy. Imaging may show diffuse interstitial changes, while biopsy reveals characteristic glycogen-rich cells in the interstitium. Additional tests, such as pulmonary function studies (when feasible) or genetic screening, may be performed to rule out associated conditions.

Treatment Options

Treatment focuses on supportive care to manage symptoms and improve lung function. This may include oxygen therapy, bronchodilators, or corticosteroids in some cases. For severe or progressive disease, lung transplantation may be considered. Management is often multidisciplinary, involving pulmonologists, neonatologists, and respiratory therapists.

Prognosis and Follow-Up

Prognosis varies, with some infants experiencing gradual improvement over time, while others may have persistent or progressive disease. Long-term follow-up is essential to monitor lung function, growth, and development. Outcomes depend on the severity of initial symptoms and response to treatment.

Complications

• Chronic respiratory failure requiring long-term oxygen support.
• Pulmonary hypertension.
• Delayed growth or developmental milestones.
• Increased susceptibility to respiratory infections.

Lifestyle & Prevention

• Avoid exposure to secondhand smoke or environmental pollutants.
• Ensure timely vaccination against respiratory infections (e.g., influenza, RSV).
• Follow recommended feeding and nutrition guidelines to support growth.
• Monitor for signs of respiratory distress and seek prompt care.

When to Seek Professional Help

Seek immediate medical attention if your child experiences:

• Sudden worsening of breathing or cyanosis.
• High fever with respiratory symptoms.
• Persistent cough or difficulty feeding.
• Unexplained fatigue or lethargy.

Tips for Medical Coders

When coding for pulmonary interstitial glycogenosis, use ICD-10-CM code J84.842. Ensure documentation supports the diagnosis, including clinical findings, imaging results, and biopsy confirmation if available. Note any associated conditions or complications to support accurate code assignment.